Clinical Project Management Office

Keyphrases

1. Parkinson's Disease 100%
2. Luxembourg 51%
3. Parkinson 37%
4. COVID-19 25%
5. Non-alcoholic Fatty Liver Disease (NAFLD) 25%
6. Luxembourgish 24%
7. Mild Cognitive Impairment 20%
8. SARS-CoV-2 Infection 19%
9. GBA1 19%
10. Meta-analysis 18%
11. Human Gut Microbiome 18%
12. General Practice 18%
13. Clinical Data 17%
14. Gut Microbiota 16%
15. Diagnostic Accuracy 15%
16. Machine Learning 14%
17. Non-invasive Test 14%
18. Biobank 14%
19. Chlamydia Screening 14%
20. Polygenic Risk Score 13%
21. Vibration-controlled Transient Elastography 13%
22. Idiopathic Parkinson's Disease 13%
23. Levodopa-induced Dyskinesia 12%
24. Long-read Sequencing 12%
25. Impulse Control Disorders 12%
26. Cross-cohort 12%
27. Outcome Prediction 12%
28. Gait Data 12%
29. Metabolomics Data 12%
30. Major Risk 12%
31. Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) 12%
32. Complex Intervention 12%
33. Interlaboratory 12%
34. GBA1 Variant 12%
35. Magnetic Resonance Elastography 11%
36. Fibrosis 10%
37. Liver Stiffness 10%
38. Metabolic Dysfunction-associated Steatohepatitis 10%
39. Advanced Fibrosis 9%
40. MicroRNA 9%
41. Screening Test 9%
42. Epigenetic Modification 9%
43. Risk Factors 9%
44. Zelen Design 9%
45. Parkinson Patients 8%
46. Peripheral Blood Mononuclear Cells 8%
47. Randomized Controlled Trial 8%
48. Multi-omics Analysis 8%
49. Risk Variant 8%
50. Microbiome 8%
51. Population-based Cohort 8%
52. Healthy Controls 8%
53. Epidemiology 7%
54. Comparative Analysis 7%
55. Educational Intervention 7%
56. Interpretable Machine Learning 7%
57. Pembrolizumab 7%
58. Vorinostat 7%
59. External Quality Assurance 7%
60. Human Gastrointestinal Tract 7%
61. Epigenome 7%
62. Coronavirus Disease (COVID) 7%
63. Preanalytical Variables 7%
64. Functional Potential 7%
65. Biospecimens 7%
66. Age of Onset 7%
67. Steatohepatitis 7%
68. Cluster Randomized Trial 7%
69. Zelen 7%
70. Histology 7%
71. Integrative multiomics 7%
72. Fibrosis-4 Index 6%
73. Human Papillomavirus 6%
74. Trial Registration 6%
75. Area under the Curve 6%
76. Pandemic Impact 6%
77. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) 6%
78. Disease Effects 6%
79. Householder 6%
80. Prospective Longitudinal Cohort 6%
81. Cardiovascular History 6%
82. Prognostic Analysis 6%
83. Dietary Model 6%
84. Disease Duration 6%
85. Dopaminergic Pathway 6%
86. Acknowledgment 6%
87. Oxygen Control 6%
88. SpO2 6%
89. Randomized Crossover Trial 6%
90. Disease Severity 6%
91. Authorship Criteria 6%
92. HPV Carcinogenesis 6%
93. Circulating Tumor DNA (ctDNA) 6%
94. Tilia 6%
95. Linden 6%
96. Allergy Epidemic 6%
97. Memory Impairment 6%
98. Open-source Tools 6%
99. Health Effects 6%
100. Healthy Adults 6%